ACADIA Pharmaceuticals Inc. Operating Income

Operating Income of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Income growth rates and interactive chart. Operating income is the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation, and cost of goods sold (COGS). Operating income–also called income from operations–takes a company's gross income, which is equivalent to total revenue minus COGS, and subtracts all operating expenses. A business's operating expenses are costs incurred from normal operating activities and include items such as office supplies and utilities. Operating income is measured before interest and tax expenses and is a good gauge of a company's operational profitability.


Highlights and Quick Summary

  • Operating Income for the quarter ending March 30, 2021 was $-66.8 Million (a -0.58% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Income increased by 51.72%
  • Annual Operating Income for 2020 was $-287 Million (a 16.24% increase from previous year)
  • Annual Operating Income for 2019 was $-247 Million (a -0.36% decrease from previous year)
  • Annual Operating Income for 2018 was $-247 Million (a -15.38% decrease from previous year)
  • Twelve month Operating Income ending March 30, 2021 was $-264 Million (a -7.94% decrease compared to previous quarter)
  • Twelve month trailing Operating Income increased by 12.11% year-over-year
Trailing Operating Income for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
$-264 Million $-287 Million $-276 Million $-235 Million
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Income of ACADIA Pharmaceuticals Inc.

Most recent Operating Incomeof ACAD including historical data for past 10 years.

Interactive Chart of Operating Income of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Operating Income for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-66.77
2020 $-67.16 $-85.9 $-44.01 $-89.52 $-286.59
2019 $-56.4 $-45.42 $-57.09 $-87.63 $-246.55
2018 $-67.28 $-61.27 $-64.08 $-54.82 $-247.44
2017 $-70.01 $-65.64 $-68.04 $-88.72 $-292.41
2016 $-78.23 $-72.4 $-71.92 $-50.26 $-272.82
2015 $-45.57 $-39.0 $-39.5 $-40.55 $-164.61
2014 $-28.56 $-24.99 $-21.72 $-17.96 $-93.23
2013 $-12.17 $-10.81 $-9.16 $-6.16 $-38.3
2012 $-6.82 $-2.41 $-5.43 $-6.23 $-20.89
2011 $-5.31 $-5.09 $-6.58 $-5.86 $-22.85
2010 $29.13 $-4.24 $-4.3 $15.09

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.